Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy
Wafaa S. Ramadan(University of Sharjah), Raafat El‐Awady(American Association of Colleges of Pharmacy)
Cited by 32
Related Papers
The impact of CBP expression in estrogen receptor-positive breast cancer
|Clinical Epigenetics|2021|37
Effect of safranal on the response of cancer cells to topoisomerase I inhibitors: Does sequence matter?
|Frontiers in Pharmacology|2022|24
Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives
|iScience|2023|8
Discovery of Novel Class of Histone Deacetylase Inhibitors as Anticancer Agents
|Research Square|2021|0